LTS Lohmann Therapie-Systeme AG
Storys zum Thema Medizin
-
Sprache:
Englisch
- Medien:
- Zeitraum:
- Zeitraum:Gesamt
- mehr
Hearing loss company Acousia announces first patient enrolled in its Phase 2 PROHEAR-Study
Tübingen, Germany (ots) - Acousia Therapeutics GmbH, a Tübingen-based clinical stage biotech company focused on the enhancement and preservation of natural hearing, just announced the randomization of the first patient for the PROHEAR-Study. The PROHEAR-Study is a placebo-controlled, Phase 2a study with split-body design, which investigates the otoprotective efficacy ...
mehrPolaroid Therapeutics completes pre-clinical milestones in the development of superior antimicrobial technology for acute and chronic wounds
Bern, Switzerland (ots/PRNewswire) - - Its proprietary innovative polymer technology reduces bacterial bioburden without triggering antimicrobial resistance, one of the top global public health threats - The Advanced Wound Dressing (AWD) market is valued at 4.5 billion USD and is witnessing increasing demand and ...
mehrINSIGHTEC MR-GUIDED FOCUSED ULTRASOUND TECHNOLOGY RECOMMENDED FOR NATIONAL COVERAGE FOR DUTCH PATIENTS LIVING WITH ESSENTIAL TREMOR
Amsterdam (ots/PRNewswire) - The Netherlands is the latest European country to recommend national coverage for the treatment of essential tremor with focused ultrasound. Insightec, a pioneer and global leader in focused ultrasound, has welcomed a positive recommendation report[1] from the Dutch Healthcare Institute ...
mehrBiomay Announces its Successful Support of Approval of First CRISPR/Cas9-based Therapy
mehrSHL Medical partners with SteriPack Group to set up final assembly service
mehrIntuitive Surgical Deutschland GmbH
Intuitive’s da Vinci Single-Port Surgical System Receives CE Mark / da Vinci SP approved for use in Europe across multiple procedures
Sunnyvale, Calif. (ots) - Intuitive (NASDAQ: ISRG), a global technology leader in minimally invasive care and the pioneer of robotic-assisted surgery, announced that the da Vinci Single-Port (SP) surgical system has received CE mark approval for use in Europe for endoscopic abdominopelvic, thoracoscopic, transoral ...
mehrEpitomee® Announces Successful Completion of Pivotal Clinical Trial for Innovative Weight Loss Capsule
Caesarea, Israel (ots/PRNewswire) - Epitomee® announces the successful completion of the RESET pivotal clinical trial, for its weight loss capsule. The randomized placebo controlled, double blind trial, investigated the safety and efficacy of Epitomee® capsule versus the sham capsule control, alongside lifestyle ...
mehrThe International Diabetes Federation (IDF)
International Diabetes Federation and Sanofi Global Health Unit collaborate to strengthen diabetes response in 40 countries
Brussels (ots/PRNewswire) - The partnership will enhance diabetes care through training aimed at building capacity among healthcare professionals in low and middle-income countries. The International Diabetes Federation (IDF), in collaboration with Sanofi's Global Health Unit (GHU), is taking significant steps to ...
mehrSIXAI is sad to announce the passing of Ran Poliakine
Neve Ilan, Israel (ots/PRNewswire) - Ran Poliakine, entrepreneur and a serial investor, passed away last Friday, January 12th, at the age of 56, due to a medical condition. Over the past 35 years, Poliakine dedicated his life to making the world a better place. He founded over 20 companies and registered hundreds of patents across various fields. In his most recent role, he served as the head of SIXAI, which integrates ...
mehrAcousia Therapeutics attracts new investor on its path to make hearing loss a treatable disease
Tübingen (ots) - - German pioneer biotech accelerates hearing loss solution development with fresh capital boost Acousia Therapeutics GmbH, a clinical-stage biotech company developing drug candidates against acute and chronic forms of hearing loss, proudly announces Esperante Ventures as the latest addition to its esteemed group of investors. The infusion of fresh ...
mehrMedison Pharma Announces Agreement with Regeneron Pharmaceuticals to Commercialize Libtayo® (cemiplimab) in Multiple Countries
Zug, Switzerland (ots/PRNewswire) - - Libtayo (cemiplimab) is a leading PD-1 inhibitor that has shown efficacy in the treatment of certain patients with cutaneous squamous cell carcinoma, advanced basal cell carcinoma, advanced non-small cell lung cancer and advanced cervical cancer, and is approved by regulatory ...
mehrBioVaxys Executes Letter of Intent for Major Immunotherapeutics Technology Acquisition
Vancouver, Bc (ots/PRNewswire) - BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF) ("BioVaxys" or "Company") announced today that it has executed a non-binding Letter of Intent ("LOI") to acquire the core platform technology and entire immunotherapeutics intellectual property portfolio of discovery, preclinical development, and Phase II clinical study ...
mehrBioVaxys and Procare Health Agree to Termination of USA Distribution Agreement for Papilocare
Vancouver, Bc (ots/PRNewswire) - BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF) ("BioVaxys" or "Company") announced today that as part of BioVaxys' efforts to refocus on immunotherapeutics, Biovaxys and Procare Health ("Procare") have jointly and amicably agreed to terminate the US Distribution Agreement for Papilocare and Immunocaps. The partnership ...
mehrPRODUCTLIFE GROUP ACQUIRES LIFEBEE, STRENGTHENING ITS CAPACITY TO SUPPORT DIGITAL TRANSFORMATION IN LIFE SCIENCES
Paris (ots/PRNewswire) - ProductLife Group (PLG), the global consulting provider of regulatory, scientific, vigilance and quality services for the life sciences industries, announces the acquisition of LifeBee, a leading Italian and Swiss based consulting firm providing digital transformation, operational excellence ...
mehrLTS Lohmann Therapie-Systeme AG
LTS receives $4.3 Million grant for the development of contraceptive Microneedle Array Patches
mehrLTS Lohmann Therapie-Systeme AG
LTS receives grant of $1.2 Million to support the development of thermostable mRNA formulations for Microneedle Array Patches
mehrTakeda Pharma Vertrieb GmbH & Co. KG
The European Commission Approves Label Update for TAKHZYRO® (lanadelumab), Expanding Its Use to a Broader Group of Paediatric Patients with Recurrent Attacks of Hereditary Angioedema (HAE)
Zurich (ots/PRNewswire) - - TAKHZYRO® is the First Routine Prevention Treatment of HAE Approved in the EU for Patients Under the Age of Six. - The therapeutical indication for TAKHZYRO® has been extended to patients aged 2 years and older.1 - Offers a New Preventative Treatment Option for young HAE patients with ...
mehrBehaVR and Fern Health Merge To Form RealizedCare, Launch Digital Care Management Platform to Unlock the Value of Digital Therapeutics
NASHVILLE, Tenn., Aachen, Germany (ots) - The merger will accelerate a new digitally-powered care management solution for chronic pain and beyond; Pharmaceutical company Grünenthal becomes the largest investor in the combined enterprise BehaVR, a pioneering force in digital therapeutics (DTx) experiences, and Fern ...
mehrBehaVR and Fern Health Merge To Form RealizedCare, Launch Digital Care Management Platform to Unlock the Value of Digital Therapeutics
NASHVILLE, Tenn., Aachen, Germany (ots) - The merger will accelerate a new digitally-powered care management solution for chronic pain and beyond; Pharmaceutical company Grünenthal becomes the largest investor in the combined enterprise BehaVR, a pioneering force in digital therapeutics (DTx) experiences, and Fern ...
mehrNew Published Study Demonstrates Safety and Feasibility of Filterlex Medical's CAPTIS® Device in Providing Embolic Protection During TAVR
Caesarea, Israel (ots/PRNewswire) - Peer-Reviewed EuroIntervention Journal Publishes First-in-Human Study Finding Filterlex Medical's CAPTIS® Embolic Protection Device Performed Well and is Safe During Transcatheter Aortic Valve Replacement (TAVR). Filterlex Medical Ltd., a cardiovascular medical device startup, ...
mehrIpsen and Medison Pharma Announce Health Canada Approval of Bylvay™ (odevixibat) for the treatment of pruritus due to Progressive Familial Intrahepatic Cholestasis (PFIC)
Zug, Switzerland and Paris (ots/PRNewswire) - Bylvay (odevixibat) is the first and only oral treatment available in Canada for the treatment of pruritus due to this rare genetic condition Today, Ipsen (Euronext: IPN) (ADR: IPSEY), a global biopharmaceutical company focused on transformative medicines in oncology, ...
mehrAntech launches first comprehensive veterinary diagnostics offering in the UK, including a new state-of-the-art reference laboratory
Warwick, England, 7 Nov. 2023 (ots/PRNewswire) - Antech to offer UK veterinary professionals a complete and flexible diagnostics portfolio spanning reference labs, in-house diagnostics, imaging and software Antech, the full-service veterinary diagnostics business that is part of the Science & Diagnostics division of ...
mehrSoterios Pharma completes Phase II enrolment for STS-01 in mild / moderate (patchy) alopecia areata
London (ots/PRNewswire) - Soterios Pharma, a privately held clinical-stage pharmaceutical company, announced today that it has completed target enrolment for its Phase II trial with STS-01 for mild / moderate (patchy) alopecia areata. Final results of the study are anticipated to be available in Q2 2024. David Fleet, CEO of Soterios Pharma, said, "This represents an ...
mehrAPRIL International strengthens its presence in Europe with the acquisition of Expat & Co in Belgium
Lyon, France and Paris (ots/PRNewswire) - APRIL Group, Europe's leading wholesale insurance broker, announces the acquisition of Expat & Co, a specialist in international health insurance in Belgium. Expat & Co is the leading independent underwriter of insurance for expatriates in Belgium and offers a platform of ...
mehrSHL Medical and Lifecore Biomedical enter co-marketing partnership agreement
mehrWorld Health Summit kicks off in Berlin / Experts from around the world meet at the most important forum on global health
Berlin (ots) - The World Health Summit 2023, the world's leading meeting for global health, began Sunday morning in Berlin. From October 15 to 17, international representatives from politics, science, business and civil society will discuss crucial issues in global health under the motto "A Defining Year for Global ...
mehrHearing Loss Company Acousia Therapeutics Green Lighted for Game-Changing Phase 2 Trial
Tübingen, Germany (ots/PRNewswire) - Acousia Therapeutics, a pioneer clinical-stage biotech company focused on the development of novel drug therapies for the prevention and treatment of acute and chronic forms of hearing loss, received approval from the German regulatory authorities (BfArM) for its groundbreaking Phase 2 clinical trial of the etiology-agnostic ...
mehrHearing Loss Company Acousia Therapeutics Green Lighted for Game-Changing Phase 2 Trial
Tübingen, Germany (ots) - Acousia Therapeutics, a pioneer clinical-stage biotech company focused on the development of novel drug therapies for the prevention and treatment of acute and chronic forms of hearing loss, received approval from the German regulatory authorities (BfArM) for its groundbreaking Phase 2 clinical trial of the etiology-agnostic otoprotectant ...
mehrEuropean Academy of Allergy and Clinical Immunology
EAACI International Severe Asthma Forum (ISAF) Hybrid 2023: Advancing Severe Asthma Care
Zurich (ots/PRNewswire) - The Organising Committee of the EAACI International Severe Asthma Forum (ISAF) is pleased to announce the upcoming ISAF Hybrid 2023 event, scheduled to take place in the historic city of Rome from October 05 to October 07, 2023. This event will unite global experts and emerging professionals to address the challenges of severe asthma and ...
mehr